Ecuador vs Tonga: Statin use vs. average non-HDL cholesterol levels
Ecuador
3.8
in 2018
Tonga
3.8
in 2018
Ecuador rank
6th
Tonga rank
6th
Statin use vs. average non-HDL cholesterol levels over time
- Ecuador
- Tonga
How they compare
Ecuador currently reports 3.8 against 3.8 in Tonga, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Ecuador ahead.
Ecuador ranks 6th and Tonga ranks 6th of 191 countries.
Ecuador has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Ecuador | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.7 | 3.6 | 0.1 | Ecuador |
| 1990s | 3.86 | 3.78 | 0.08 | Ecuador |
| 2000s | 3.9 | 3.8 | 0.1 | Ecuador |
| 2010s | 3.82 | 3.8 | 0.0222 | Ecuador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Ecuador or Tonga?
- Ecuador, at 3.8 against 3.8 in Tonga as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Ecuador and Tonga?
- 0, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and Tonga?
- 39 years are reported by both, from 1980 to 2018.
- How do Ecuador and Tonga rank globally for statin use vs. average non-hdl cholesterol levels?
- Ecuador ranks 6th and Tonga ranks 6th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.